小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究

丁小英; 吴剑秋; 张晓梅; 汤唯艳; 冯继锋; 寇莹莹; 汤依群

doi:10.16462/j.cnki.zhjbkz.2016.06.014

小分子VEGFR-TKI治疗晚期肾透明细胞癌致甲状腺功能减低研究

doi: 10.16462/j.cnki.zhjbkz.2016.06.014

1. 中国药科大学临床药学教研室, 江苏南京 210009;
2. 江苏省肿瘤医院肿瘤内科, 江苏南京 210009

基金项目:

江苏省卫生计生委2015年度科研课题（H201511）；江苏省2014年度普通高校研究生实践创新计划项目（SJLX-0290）

详细信息

作者简介:
丁小英(1988-),女,宁夏同心人,在读硕士研究生。主要研究方向:肿瘤药物不良反应监测。

中图分类号: R730.267;R181
计量
- 文章访问数: 248
- HTML全文浏览量: 47
- PDF下载量: 31
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-07
- 修回日期: 2016-03-29

Study on hypothyroidism caused by treating metastatic clear cell renal cell carcinoma with small molecule VEGFR-TKI

1. Research Division of Pharmacology, China Pharmaceutical University, Nanjing 210009, China;
2. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China

摘要

摘要: 目的探讨小分子第二代血管内皮生长因子受体抑制剂（vascular endothelial growth factor receptor tyrosine kinase inhibitor,VEGFR-TKI）治疗晚期肾透明细胞癌致甲状腺功能减低的发生及其疗效。方法对2009年11月～2010年12月本院收治的24例晚期肾透明细胞癌患者，其中索拉非尼或阿昔替尼组10例，对照组（细胞因子）14例。分析甲状腺功能指标的变化趋势及其预后。结果 TKI组甲减的发生率50.0%，高于对照组甲减发生率7.1%（χ²=5.714,P=0.017）。甲减发生的中位生存时间56.2个月，甲功检测表现为促甲状腺激素明显升高伴血清游离甲状腺素（free thyroxine,FT4）同步下降，但游离三碘甲状腺原氨酸（free triiodothyronine,FT3）下降时间较为滞后。TKI组和对照组中位生存时间分别为：21.0个月（95% CI：0.001～54.200）和15.0个月（95% CI：4.000～26.000；P=0.265）。结论小分子VEGFR-TKI治疗晚期转移性肾透明癌，TKI组甲减的发生率较对照组升高，生存时间较长。甲减可能是较常见的毒副反应，甲状腺功能的长期监测和甲减的适时干预，有助于提高患者治疗依从性和改善生存质量。
- 肾肿瘤 /
- 甲状腺功能减退症 /
- 流行病学方法
Abstract: Objective To investigate the incidence of hypothyroidism and efficacy of metastatic clear cell renal cell carcinoma treated with small molecule VEGFR-TKI. Methods A retrospective study was conducted to analyze the clinical data of 24 patients treated with TKI (Axitinib or Sorafenib) therapy(n=10) or cytokine therapy(n=14) from November 2009 to December 2010. The change trend of thyroid function index and prognosis between TKI group and control group were analyzed. Results TKI group with hypothyroidism was higher than control group(50.0% vs. 7.1%, χ²=5.714, P=0.017). The median time of hypothyroidism was 56.2 months, thyroid stimulating hormone (TSH) increased obviously, free thyroxine (FT4) decreased synchronously and free triiodothyronine (FT3) fall time was relatively lagging behind in TKI group. The median overall survival was 21(95% CI:0.001-54.200) months of TKI group versus 15(95% CI:4.000-26.000) months of control group (P=0.265). Conclusions The incidence of hypothyroidism of TKI group is significantly higher than the control group, the survival time is longer. The hypothyroidism is a common side effect of metastatic clear cell renal carcinoma patients receiving small molecule VEGFR-TKI. Long term monitoring thyroid function and timely intervention of hypothyroidism can improve the patient's treatment compliance and quality of life.
- Kidney neoplasms /
- Thyroid hypofunction /
- Epidemiologic methods

HTML全文

参考文献(19)

Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage:a new system to predict metastasis for patients with localized renal-cell-carcinomas [J]. Clin Cancer Res, 2008,14(17):5579-5584.

Shariat SF, Bolenz C, Karakiewicz PI. Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double -blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators [J]. Eur Urol, 2008,54(4):948-949.

Kakehi Y. Molecular targeted therapy for renal cell carcinoma [J]. Rinsho Ketsueki, 2008,49(8):622-625.

Cella D, Cappelleri JC, Bushmakin A, et al. Quality of life predicts progression free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa [J]. J Oncol Pract, 2009,5(2):66-70.

Culp SH, Wood CG. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double -blind, randomized, placebo controlled phase III trial [J]. Eur Urol,2009,55(6):1484-1485.

Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma [J]. Drugs R D, 2011,11(2):113-126.

Wilhelm S, Chien DS. BAY 43-9006: preclinical data [J]. Curr Pharm Des, 2002,8(25):2255-2257.

Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms [J]. Cancer Treat Rev, 2014,40(7):883-891.

Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow [J]. Oncologist, 2011,16(Suppl 2):45-50.

Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal carcinoma [J]. J Clin Oncol, 2004,22(3):454-463.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2014,25 Suppl 3:iii49-iii56.

Peréz-Solert R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining [J]. J Clin Oncol, 2005,23(22):5235-5246.

余国芳,林丽珠. 林丽珠辨治表皮生长因子受体抑制剂相关皮疹的经验探析 [J]. 世界科学技术˙中医药现代化, 2009,12(5):758-762.

Grünwald V, Soltau J, Ivanyi P,et al. Molecular targeted therapies for solid tumors: management of side effects [J]. Onkologie. 2009,32(3):129-138.

Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone and biomarkers: a phase I study in Japanese patients [J]. Cancer Sci, 2010,101(4):963-968.

Viktor Grünwald, Axel S Merseburger. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [J]. Onco Targets Ther,2012,5:111-117.

Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma:An expanded-access trial [J]. Lancet Oncol, 2009,10(8):757-763.

Clemons J, Gao D, Naam M, et al. Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib [J]. Clin Genitourin Cancer, 2012,10(4): 225-231.

Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in advanced renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial [J]. Jpn J Clin oncol, 2013,43(6):616-628.

施引文献

资源附件(0)

访问统计